Be Your Best Self
- 192 pages
- 7 hours of reading
Based on Mike Bayer's New York Times bestseller Best Self, a motivational, do- it-yourself workbook teaching you how to reinvent your life and live every day as your Best Self.
Mike Bayer Books
Mike Bayer, known as Coach Mike, is the Founder and CEO of CAST Centers. As a personal development coach, he has empowered numerous families, executives, and artists to break free from destructive patterns and cycles. His work focuses on enabling individuals to achieve positive change and unlock their full potential. Bayer's approach emphasizes practical strategies for overcoming obstacles and fostering sustainable growth.
By working through each of the Seven SPHERES of life-Social, Personal, Health, Education, Relationships, Employment and Spiritual Development-Best Self is an accessible and interactive book that distills all of Coach Mike's wisdom into a compact, focused guide that will ignite anyone's desire for change.
One Decision
- 352 pages
- 13 hours of reading
"One Decision is a shift in thinking and a powerful blueprint that will catapult you into action, helping you turn obstacles into opportunities, struggles into successes and create a new outlook to improve your outcomes while living out the days ahead"-- Provided by publisher
Investieren in Biotechnologie
Chancen, Risiken, Möglichkeiten - simplified
- 228 pages
- 8 hours of reading
In "Investieren in Biotechnologie" gelingt Bengs und Bayer der Spagat zwischen der Erläuterung wissenschaftlicher Errungenschaften und dem Aufzeigen von Chancen für den risikobewussten Anleger. Ohne sich in Details zu verlieren, werden die verschiedenen Biotechnologiemärkte und Investitionsmöglichkeiten in Form von Aktien, Zertifikaten, Publikums- und Private-Equity-Fonds und anderen Anlageformen dargstellt. Das Buch gibt Antworten auf die Frage, wo sich ein langfristiges Biotech-Investment lohnt, erläutert die Zusammenhänge zwischen Chancen und Risiken und gibt viele weiterführende Informationshinweise für den darüber hinaus interessierten Biotech-Investor.
